Target Lesion Failure (TLF) and Target Lesion Revascularization (TLR) rates in BIOSOLVE-II and III remain low and comparable to 2nd generation drug-eluting stents out to 24 months
No definite or probable Scaffold Thrombosis (ST) were reported up to 24 months
Study design Pooled analysis of BIOSOLVE-II and BIOSOLVE-III, two prospective clinical trials.Endpoints Primary endpoints
BIOSOLVE-II: In-segment LLL at 6-month follow-up
BIOSOLVE-III: Procedural success
Secondary endpoints (selected)
TLF defined as a composite of cardiac death, Target-Vessel Myocardial Infarction (MI) and Clinically-Driven Target Lesion Revascularization (CD-TLR) at 12 months
Definite/probable ST at 12 months
Prof. M. Haude, Lukaskrankenhaus, Neuss, Germany 1. Haude M. Imaging and Clinical Results with the latest Magmaris Magnesium-Based Scaffold, presented at: TCT, September 22, San Diego, USA; 2. TLF defined as a composite of cardiac death, Target-Vessel Myocardial Infarction (TV MI) and Clinically-Driven Target Lesion Revascularization and CABG. All events have been adjudicated by a clinical events committee; 3. Peri-procedural MI according to SCAI definition and spontaneous MI according to the Extended Historical definition.
Do you want to leave the current website?
You are leaving now the xxx Website and will be forwarded to the xxx website.